

VOS-44 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Hans Weiher, et al.  
Application No. : 10/644,325 Confirmation No.: 6657  
Filed : August 19, 2003  
For : USE OF  $\gamma$ -GT INHIBITORS FOR THE TREATMENT  
OF DEGENERATIVE DISEASES  
Group Art Unit : 1623  
Examiner : Not yet assigned

New York, New York 10020  
January 21, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR  
INFORMATION DISCLOSURE STATEMENT

Sir:


Transmitted herewith is an Information Disclosure Statement in the  
above-identified application. This Statement is submitted:

- ☐ within three months of the application filing date;  
☒ more than three months from the application  
filing date but before the mailing date of the first  
Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of this Statement  
requires no fee. However, if for any reason a fee is due, the Director is hereby  
authorized to charge payment of any fees required in connection with this Information


Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,

  
\_\_\_\_\_  
Jane T. Gunnison (Reg. No. 38,479)  
Attorney for Applicants  
Shawn-Marie Mayrand (Reg. No. 48,986)  
R. Minako Pazdera (Reg. No. 46,984)  
Agents for Applicants  
c/o FISH & NEAVE  
Customer No. 1473  
1251 Avenue of the Americas  
New York, New York 10020-1104  
Tel.: (212) 596-9000  
Fax.: (212) 596-9090

I hereby certify that this  
Correspondence is being  
deposited with the U.S.  
Postal Service as First  
Class Mail in an envelope  
Addressed to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450 on

January 21, 2004  
Lillian Garcia

  
\_\_\_\_\_  
Signature of Person Signing



VOS-44 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not yet assigned  
Group : 1623  
Applicant : Hans Weiher, et al.  
Application No. : 10/644,325 Confirmation No. 6657  
Filed : August 19, 2003  
For : USE OF  $\gamma$ -GT INHIBITORS FOR THE TREATMENT  
OF DEGENERATIVE DISEASES

New York, New York 10020  
January 21, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants, through their representatives, make of record the following documents,<sup>1</sup> copies of which are submitted herewith:

United States Patent Documents

<u>Patent No.</u>	<u>Name</u>	<u>Issued</u>
4,758,551	Meister et al.	July 19, 1988

---

<sup>1</sup> For the Examiner's convenience, applicants have enclosed a completed Form PTO-1449, listing these documents.

### Articles

Evans, P., Halliwell, B. "Free Radicals and Hearing: Cause, Consequence, and Criteria," *Annals New York Academy of Sciences*, 884:19-40 (1999).

Hanigan, M. H. et al. "Cisplatin nephrotoxicity: Inhibition of  $\gamma$ -Glutamyl Transpeptidase Blocks the Nephrotoxicity of Cisplatin without Reducing Platinum Concentrations in the Kidney," *American Journal of Obstetrics and Gynecology*, 175:270-274 (1996).

Hanigan, M. H. et al. "Expression of Gamma-Glutamyl Transpeptidase in Stage III and IV Ovarian Surface Epithelial Carcinomas Does Not Alter Response to Primary Cisplatin-Based Chemotherapy," *Database Biosis* (1998).

Hanigan, M. H. et al. "Human Germ Cell Tumours: Expression of Gamma-Glutamyl Transpeptidase and Sensitivity to Cisplatin," *British Journal of Cancer* 81:75-79 (1999).

Isao, N. et al. "Attenuation of Aminoglycoside Ototoxicity by Glutathione," *Database Biosis Online!* (1996).

Kil, J. et al. "Localization of Gamma-Glutamyl Transpeptidase in the Chick Inner Ear Sensory Epithelia," *Society for Neuroscience*, 22:1621 (1996).


Lopez-Gonzalez, M. A. et al. "Ototoxicity Caused by Cisplatin is Ameliorated by Melatonin and Other Antioxidants," *Journal of Pineal Research*, 28:73-80 (2000).

Townsend, D. M. et al. "In Vivo Metabolism of Cisplatin to a Nephrotoxin by Gamma-Glutamyl Transpeptidase and Beta-Lyase." *Proceedings of the American Association for Cancer Research Annual*, 41:266 (2000).

Applicants respectfully request that these documents be (1) considered by the Examiner prior to issuance of any patent from this application; and (2) printed on any patent that may issue from this application. Applicants also request that a

copy of enclosed Form PTO-1449, as considered and initialed by the Examiner, be returned with the next communication.


Respectfully submitted,


  
\_\_\_\_\_  
Jane T. Gunzison (Reg. No. 38,479)  
Attorney for Applicants  
Shawn-Marie Mayrand (Reg. No. 48,986)  
R. Minako Pazdera (Reg. No. 46,984)  
Agents for Applicants  
FISH & NEAVE  
Customer No. 1473  
1251 Avenue of the Americas  
New York, New York 10020-1105  
Tel.: (212) 596-9000  
Fax: (212) 596-9090

I hereby certify that this  
Correspondence is being  
deposited with the U.S.  
Postal Service as First  
Class Mail in an envelope  
Addressed to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450 on

January 21, 2004

Lillian Garcia

  
\_\_\_\_\_  
Signature of Person Signing


**U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTS**
**ATTY. DOCKET NO.**  
VOS-44 CON

**APPLICATION NO.**  
10/644,325

**APPLICANTS**  
Hans Weiher, et al.

**CONFIRMATION NO.**  
6657

**FILING DATE**  
August 19, 2003

**GROUP**  
1623

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,758,551	7/19/88	Meister et al.	514	18	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

EXAMINER INITIAL	
	Evans, P., Halliwell, B. "Free Radicals and Hearing: Cause, Consequence, and Criteria," <i>Annals New York Academy of Sciences</i> , 884:19-40 (1999)
	Hanigan, M. H. et al. "Cisplatin nephrotoxicity: Inhibition of $\gamma$ -Glutamyl Transpeptidase Blocks the Nephrotoxicity of Cisplatin without Reducing Platinum Concentrations in the Kidney," <i>American Journal of Obstetrics and Gynecology</i> , 175:270-274 (1996)
	Hanigan, M. H. et al. "Expression of Gamma-Glutamyl Transpeptidase in Stage III and IV Ovarian Surface Epithelial Carcinomas Does Not Alter Response to Primary Cisplatin-Based Chemotherapy," <i>Database Biosis</i> (1998)
	Hanigan, M. H. et al. "Human Germ Cell Tumours: Expression of Gamma-Glutamyl Transpeptidase and Sensitivity to Cisplatin," <i>British Journal of Cancer</i> , 81:75-79 (1999)
	Isao, N. et al. "Attenuation of Aminoglycoside Ototoxicity by Glutathione," <i>Database Biosis Online!</i> (1996)
	Kil, J. et al. "Localization of Gamma-Glutamyl Transpeptidase in the Chick Inner Ear Sensory Epithelia," <i>Society for Neuroscience</i> , 22:1621 (1996)
	Lopez-Gonzalez, M. A. et al. "Ototoxicity Caused by Cisplatin is Ameliorated by Melatonin and Other Antioxidants," <i>Journal of Pineal Research</i> , 28:73-80 (2000)
	Townsend, D. M. et al. "In Vivo Metabolism of Cisplatin to a Nephrotoxin by Gamma-Glutamyl Transpeptidase and Beta-Lyase," <i>Proceedings of the American Association for Cancer Research Annual</i> , 41:266 (2000)

**EXAMINER**
**DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.